Jounce Therapeutics to Present at Upcoming Investor Conferences in September
Jounce Therapeutics (NASDAQ: JNCE), a clinical-stage immunotherapy company, announced participation in multiple investor conferences this September. Key events include the Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Baird's Global Healthcare Conference on September 15, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29. Live webcasts will be available on Jounce's website, with replays archived for 30 days post-presentation.
- None.
- None.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September:
- 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday September 10, 2021 at 8:00 a.m. ET.
- H.C. Wainwright 23rd Annual Global Investment Conference: Presentation will be available on-demand during the conference, starting on Monday, September 13, 2021 at 7:00 a.m. ET.
- Baird’s 2021 Global Healthcare Conference: Presentation on Wednesday, September 15, 2021 at 12:15 p.m. ET.
- 2021 Cantor Fitzgerald Virtual Global Healthcare Conference: Presentation on Wednesday, September 29, 2021 at 4:00 p.m. ET.
A webcast of the presentations will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce obtained IND clearance for and exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com
Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com
FAQ
What conferences will Jounce Therapeutics participate in September 2021?
What time is Jounce's presentation at the Wells Fargo Virtual Healthcare Conference?
Where can I watch the webcasts for Jounce's investor presentations?
How long will the webcasts for Jounce's presentations be available?
What is Jounce Therapeutics' focus in cancer treatment?
